#KALV to 20I see a nice potential here.
The market is rebounding from the lower edge of the channel at the .618 fib level.
PT 20 and SL 10
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.54 USD
−126.64 M USD
0.00 USD
29.87 M
About KalVista Pharmaceuticals, Inc.
Sector
CEO
Benjamin L. Palleiko
Headquarters
Cambridge
Website
Founded
2004
FIGI
BBG0026ZG5B0
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Next resistance 35% upPrice has been consolidation for some time, hard to say exactly since when but for more than a year. This stock is very explosive it can jump 35% in one week. The 11 resistance is the key, if it breaks out the next immediate resistance is at 14.6. Worth the shot.
KALV Stock -12/9/2022-• Trend is technically bullish, prices contained in an ascending channel
• Bulls need to clear first resistance at 17 before prices can resume the rally
• Second stiff resistance is at 20
• As highlighted on the chart, 20 level was acting as a resistance in late 2020 and turned into support in 2021
$KALV Reports Positive Results for KVD900 Phase 2$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Her
$KALV Kalvista Pharma Trend Break
Major Downtrend broken
Broken above 200ma
Volume increased
MACD reversed
RSi in bullish uptrend
This likely has further to dropWill be watching to see where this one goes. I like that long term uptrend. If it gets near 19 - 18.90 could be a low risk swing trade.
KALV - Upward momentum long KALV looking very strong, its on a tear at the moment. It has big insider buying and strong twiggs money flow index. We think it will continue upward.
For ideal entry we would look for a upward break or pull back to 11 support area.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of KALV is 11.41 USD — it has increased by 2.06% in the past 24 hours. Watch KalVista Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange KalVista Pharmaceuticals, Inc. stocks are traded under the ticker KALV.
KALV stock has risen by 10.88% compared to the previous week, the month change is a 1.88% rise, over the last year KalVista Pharmaceuticals, Inc. has showed a 37.80% increase.
We've gathered analysts' opinions on KalVista Pharmaceuticals, Inc. future price: according to them, KALV price has a max estimate of 39.00 USD and a min estimate of 18.00 USD. Watch KALV chart and read a more detailed KalVista Pharmaceuticals, Inc. stock forecast: see what analysts think of KalVista Pharmaceuticals, Inc. and suggest that you do with its stocks.
KALV reached its all-time high on Jun 8, 2015 with the price of 129.16 USD, and its all-time low was 4.12 USD and was reached on Oct 19, 2022. View more price dynamics on KALV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KALV stock is 4.30% volatile and has beta coefficient of 1.05. Track KalVista Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is KalVista Pharmaceuticals, Inc. there?
Today KalVista Pharmaceuticals, Inc. has the market capitalization of 493.09 M, it has decreased by −7.21% over the last week.
Yes, you can track KalVista Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
KalVista Pharmaceuticals, Inc. is going to release the next earnings report on Dec 5, 2024. Keep track of upcoming events with our Earnings Calendar.
KALV earnings for the last quarter are −0.87 USD per share, whereas the estimation was −0.92 USD resulting in a 4.92% surprise. The estimated earnings for the next quarter are −0.93 USD per share. See more details about KalVista Pharmaceuticals, Inc. earnings.
KalVista Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
KALV net income for the last quarter is −40.44 M USD, while the quarter before that showed −44.65 M USD of net income which accounts for 9.42% change. Track more KalVista Pharmaceuticals, Inc. financial stats to get the full picture.
No, KALV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 150.00 employees. See our rating of the largest employees — is KalVista Pharmaceuticals, Inc. on this list?
Like other stocks, KALV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KalVista Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KalVista Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KalVista Pharmaceuticals, Inc. stock shows the sell signal. See more of KalVista Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.